Русский
Possibilities Of Antiangiogenic Therapy In Recurrent High-grade Malignant Gliomas
A.V. Smolin, G.L. Kobyakov, A.V. Konev, S.N. Nikolaeva, Yu.E. Shamanskaya, T.G. Solovei
Possibilities of antiangiogenic therapy in recurrent high-grade malignant gliomas
We consider the current possibilities in the treatment of gliomas. It is noted that despite aggressive treatment, including surgical oncotomy and chemotherapy, all gliomas recurs. In case of recurrence or continued growth of the tumor reoperation, re-radiation therapy, chemotherapy or a combination of methods can be considered as optional treatment approach. Recent studies have demonstrated high efficacy and safety of bevacizumab (Avastin) use in the treatment of patients with recurrent high-grade malignant gliomas after chemoradiotherapy using both in monotherapy and in combination with irinotecan. We have demonstrated experience on bevacizumab use in nine patients with anaplastic astrocytoma or glioblastoma.
We consider the current possibilities in the treatment of gliomas. It is noted that despite aggressive treatment, including surgical oncotomy and chemotherapy, all gliomas recurs. In case of recurrence or continued growth of the tumor reoperation, re-radiation therapy, chemotherapy or a combination of methods can be considered as optional treatment approach. Recent studies have demonstrated high efficacy and safety of bevacizumab (Avastin) use in the treatment of patients with recurrent high-grade malignant gliomas after chemoradiotherapy using both in monotherapy and in combination with irinotecan. We have demonstrated experience on bevacizumab use in nine patients with anaplastic astrocytoma or glioblastoma.
Similar Articles
